Trial Profile
A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2020
Price :
$35
*
At a glance
- Drugs Levomilnacipran (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 03 Sep 2019 Status changed from recruiting to completed.
- 22 Jan 2019 Planned End Date changed from 21 Dec 2018 to 20 Dec 2019.
- 22 Jan 2019 Planned primary completion date changed from 21 Dec 2018 to 20 Dec 2019.